2024-03-29, Fri.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Science & Technology


Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand

Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)
Date: 2021-09-17

Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand
Travere receives a USD 55 million upfront payment and is eligible for additional regulatory and commercial milestones, as well as tiered royalties on net sales

ST. GALLEN, SWITZERLAND & SAN DIEGO, CALIF.-- September 17, 2021 -- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal phase-III clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease. There are currently no approved medicines indicated for FSGS or IgAN. Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN and FSGS in the U.S. and Europe.

Under the terms of the agreement, Vifor Pharma will receive exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand. Travere will receive an upfront payment of USD 55 million and be eligible for up to USD 135 million in payments tied to the achievement of certain regulatory and market access related milestones. Vifor Pharma will also make further payments in the form of sales milestones, and tiered double-digit royalties on net sales of sparsentan in Europe, Australia and New Zealand up to 40 percent at the high end of the royalty range.

“This agreement highlights that Vifor Pharma has become a company of choice for organizations committed to partnering innovative nephrology assets”, Abbas Hussain, CEO of Vifor Pharma Group commented. “With sparsentan, we will further expand our growing nephrology pipeline into FSGS and IgAN. There are currently no effective or approved therapies for these two rare kidney disorders, resulting in a significant unmet medical need among these patient populations. We look forward to working closely with Travere, who is responsible for the ongoing clinical development program of sparsentan, and to leveraging our commercial expertise to bring this highly promising, innovative treatment option to potentially more than 150,000 patients living with IgAN or FSGS in the licensed territories as soon as possible.”

“Our goal is for sparsentan to become the new global treatment standard for people living with FSGS and IgAN; this collaboration marks an important step forward in this journey,” said Eric Dube, Ph.D., chief executive officer of Travere Therapeutics. “Vifor Pharma is a global leader in nephrology with established commercialization expertise in Europe, Australia and New Zealand and this agreement aligns our two companies with the common goal of maximizing the number of people who can access sparsentan, if approved in these regions. In addition, this collaboration will further strengthen our financial foundation and allow our organization to focus on planned future launches of sparsentan in the U.S.”

Following the recently announced positive topline interim results from the ongoing pivotal phase-III PROTECT study of sparsentan in IgAN, Travere and Vifor Pharma will further evaluate the regulatory strategy for sparsentan in Europe, including the potential to submit a joint marketing authorization application for both FSGS and IgAN in 2022. Ultimately, the responsibility for and control over marketing authorizations in the licensed territories will be transitioned to Vifor Pharma. If sparsentan is approved, Vifor Pharma will be responsible for all commercialization activities in the licensed territories. Travere remains responsible for the clinical development of sparsentan and will retain all rights to sparsentan in the U.S. and rest of the world.



 to the Top List of News

Notice of Commencement of Operation of Dexerials Photonics Solutions Corporation as Integrated Company Leading Growth in the Photonics Domain
Alphawave Semi and InnoLight Collaborate to Demonstrate Low Latency Linear Pluggable Optics with PCIe 6.0 Subsystem Solution for High-Performance AI
Medisca Opens MAZ Lab in Arizona: An Innovation and Customer Resource Center
Quectel and The Things Industries Announce Partnership to Boost Module Service Management Through LoRaWAN Integration
Efinix Rolls Out Line of FPGAs to Accelerate and Adapt Automotive Designs and Applications
StarFive¡¯s RISC-V Based JH-7110 Intelligent Vision Processing Platform Adopted VeriSilicon¡¯s Display Processor IP
Uniphore Unveils Enhanced Interaction Analytics Solution Powered by Generative AI

 

Laserfiche Announces 2024 Run Smarter Award Winners
LambdaTest and Inflectra Partner to Offer Enhanced Application Lifecyc...
The LYCRA Company joins Performance Days seminar on textile recycling
New Oracle Database Survey Shows Customers Satisfied with Current Rele...
Toshiba Adds New Position Estimation Control Technology to Its Motor C...
Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai
Ventiva Announces Partnership with Clarion for Mass Production of ICE ...
FPT Software Expands Presence in South Korea With Daegu Office Launch
Quectel IoT Modules Significantly More Secure Than Industry Average Ac...
Kymeta Begins Fulfilling Customer Orders of its First Multi-Orbit, On-...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.